BioNTech (BNTX) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $23.04B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | DE | CEO | Ugur Sahin |
| IPO Date | 2019-10-10 | CAGR | 60.82% |
| Employees | 7,807 | Website | www.biontech.de |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $9.53B | P/E | -19.72 | Forward P/E | -21.05 | PEG | — |
| P/S | 8.26 | P/B | 1.24 | P/CF | 26.53 | P/FCF | 33.93 |
| Sales | $3.26B | Sales 1Y | 1.91% | Sales 3Y | -77.08% | Sales 5Y | 11.81% |
| EPS | $-4.62 | EPS 1Y | — | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | -86.65% | EPS QoQ | 73.98% | Sales QoQ Avg | 99.4% | EPS QoQ Avg | 224.74% |
| Gross Margin | 77.6% | Operating Margin | -52.06% | Profit Margin | -44.67% | ROCE | -7.54% |
| ROA | -6% | ROE | -7% | Altman Z Score | 6.87 | Piotroski Score | 4 |
| Current Ratio | 8.8 | Quick Ratio | 8.74 | Cash Ratio | 5.63 | Op. CF Ratio | -0.24 |
| Debt/Equity | 0.02 | Debt/Assets | 0.01 | Lt Debt/Equity | 0.01 | Lt Debt/Cap. | 0.01 |
| Intrst Cov. | -67.92 | Inventory Turnover | 6.03 | Asset Turnover | 0.13 | Receivables Turnover | 4.57 |
| Enterprise Value | $9.53B | P/E Ratio | -19.72 |
| Forward P/E | -21.05 | PEG Ratio | — |
| P/S Ratio | 8.26 | P/B Ratio | 1.24 |
| P/CF Ratio | 26.53 | P/FCF Ratio | 33.93 |
| EPS | $-4.62 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 1.91% | Gross Margin | 0.78% |
| Operating Margin | -0.52% | Profit Margin | -0.45% |
| ROE | -0.07% | ROA | -0.06% |
| ROCE | -0.08% | Current Ratio | 8.8 |
| Quick Ratio | 8.74 | Cash Ratio | 5.63 |
| Debt/Equity | 0.02 | Interest Coverage | -67.92 |
| Altman Z Score | 6.87 | Piotroski Score | 4 |
BioNTech (BNTX) valuation & financials
BioNTech (BNTX) has a market capitalization of $23.04B and trades at a price-to-earnings ratio of -19.7. It operates in the Healthcare sector (Biotechnology).
BioNTech's revenue grew +1.9% over the last year.
BioNTech's next earnings report is scheduled for August 3, 2026 before market open; analysts estimate EPS of $-2.40.
BioNTech (BNTX) — frequently asked questions
When does BioNTech (BNTX) report earnings next?
BioNTech is expected to report earnings on August 3, 2026 before market open. Analysts estimate EPS of $-2.40.
What is BioNTech's market cap?
BioNTech (BNTX) has a market capitalization of $23.04B.
What is BNTX's P/E ratio?
BioNTech trades at a price-to-earnings ratio of -19.7, with trailing twelve-month EPS of $-4.62.
How fast is BioNTech growing?
BioNTech's revenue grew +1.9% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)